Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps

12/01/2020 | 12:12pm EST

By Colin Kellaher

Novartis AG and Roche Holding AG's Genentech unit on Tuesday said the Food and Drug Administration approved the expanded use of Xolair for the add-on maintenance treatment of nasal polyps in adults with inadequate response to intranasal corticosteroids.

The companies said the approval makes Xolair the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E, a key driver of inflammation.

Nasal polyps, which can lead to nasal congestion and a loss of smell, frequently occur with other respiratory conditions, such as allergies and asthma.

Xolair was already approved in the U.S. to treat moderate to severe persistent allergic asthma and chronic idiopathic urticaria. Novartis and Genentech work together to develop and co-promote Xolair in the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-01-20 1211ET

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 2.13% 85.3 Delayed Quote.1.97%
ROCHE HOLDING AG 1.47% 316.65 Delayed Quote.2.48%
All news about NOVARTIS AG
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
01/15NOVARTIS AG : Gets a Buy rating from Deutsche Bank
MD
01/15NOVARTIS : Exane BNP Paribas Lowers Price Target on Novartis, Maintains Outperfo..
MT
01/14Invitae to Develop Standardized Panel to Detect Molecular Residual Disease as..
MT
01/14NOVARTIS : Gets FDA Breakthrough-Therapy Designation for Ligelizumab
DJ
01/14NOVARTIS AG : UBS maintains a Buy rating
MD
01/14NOVARTIS' : Ligelizumab Receives FDA Breakthrough Therapy Designation for Urtica..
MT
01/14NOVARTIS : Skin Disease Treatment Ligelizumab Gets US FDA's Breakthrough Therapy..
MT
01/14NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language
AQ
01/14NOVARTIS : ligelizumab (QGE031) receives FDA Breakthrough Therapy designation fo..
PU
More news
Financials (USD)
Sales 2020 49 176 M - -
Net income 2020 8 396 M - -
Net Debt 2020 19 973 M - -
P/E ratio 2020 26,0x
Yield 2020 3,31%
Capitalization 218 B 218 B -
EV / Sales 2020 4,83x
EV / Sales 2021 4,42x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 109,22 $
Last Close Price 95,66 $
Spread / Highest target 47,2%
Spread / Average Target 14,2%
Spread / Lowest Target -14,1%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans JŲrg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG1.97%218 041
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120